BridgeBio Pharma reported $71.5 million in net product revenue for Attruby in the second quarter of 2025, marking its first full quarter of U.S. sales. Since the launch, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers as of August 1, 2025, with an acceleration in new patient additions despite emerging competition. The company added approximately 1,679 unique patients in the 14 weeks since the last update, averaging about 120 new patients per week. Analysts from Bank of America, Wells Fargo, Piper Sandler, Mizuho, and Cowen have issued positive outlooks on BridgeBio, raising price targets to between $58 and $76. They highlighted the growing market share among treatment-naive patients and expect sales growth driven by increased use of free drug programs and patient assistance programs. Management anticipates that treatment-naive patients may receive Attruby for an average of three to four years, contributing to a longer lifetime treatment duration compared to patients who switch therapies. Separately, Assembly Biosciences announced a $175 million equity financing and reported positive interim Phase 1b clinical results for its long-acting helicase-primase inhibitor candidate ABI-5366 in recurrent genital herpes. Additionally, BioVie priced a $12 million public offering to support clinical programs in liver and neurodegenerative diseases, and Gilead Sciences agreed to purchase 2.3 million shares of Assembly Biosciences in a private placement.